Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.40 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28982625 | 0.81 | CES2 (0.48) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL20072836 | 0.81 | CES2 (0.48) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL1475613 | 0.81 | CES2 (0.48) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL28243558 | 0.77 | CES2 (0.58) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL28402017 | 0.75 | CES2 (0.56) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL26121122 | 0.75 | MAOA (0.57) | CES2CES1PTPN1 | |
| SCHEMBL1360049 | 0.74 | PTPN1 (0.68) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL16795803 | 0.74 | GRIN2B (0.43) | GRIN2BHDAC1 | |
| SCHEMBL928167 | 0.73 | CES2 (0.54) | CES2CES1PTPN1GSK3BSRD5A2 | |
| SCHEMBL22746994 | 0.73 | CES2 (0.54) | CES2CES1PTPN1GSK3BSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3433239-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | University of Pittsburgh- Of the Commonwealth System of Higher Education (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017165822-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-09-28 | — | — | WO | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7728022-B2 | (3-phenyl-1-{1-[4-(trifluoromethyl)phenyl]butyl}-4,5,6,7-tetrahydro-1H-indol-7-yl)acetic acid, used for treating diseases associated with the deposition of beta -amyloid peptide in the brain | MERCK SHARP & DOHME LTD. (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1748982-B1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2007-10-04 | — | — | US | disclosed |
| WO-2005108362-A1 | (4, 5, 6, 7-TETRAHYDRO-1-H-INDOL-7-YL) ACETIC ACID DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | CES2 2509/4885CES1 1072/4885PTPN1 2304/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | CES2 2875/4885CES1 1204/4885PTPN1 2230/4885 |
| US-20070232678-A1 | (4, 5, 6, 7-Tetrahydro-1-H-Indol-7-Yl) Acetic Acid Derivatives for Treatment of Alzheimer's Disease | APP, BACE1, CHAT | CES2 2407/4885CES1 1057/4885PTPN1 4578/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | CES2 2818/4885CES1 1179/4885PTPN1 2244/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | CES2 2818/4885CES1 1179/4885PTPN1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.